Hahn discusses his recent study evaluating AREDS’s potential for nonsubfoveal GA regression in response to a recent post hoc analysis.
Paul Hahn, MD, PhD, FASRS
Advertisement
Articles by Paul Hahn, MD, PhD, FASRS
Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.
Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.
Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.
Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
Advertisement
Latest Updated Articles
Novel Investigational Approaches for the Treatment of Neovascular AMDNovember 30th 2023
Novel Investigational Approaches For the Treatment of Neovascular AMDDecember 11th 2023
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
3
Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD
4
FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life
5